[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555571":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":46,"collaborators":48,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":20,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Yale University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pharmacist lead intervention","EXPERIMENTAL","Clinical pharmacists will be trained by a team with expertise in behavioral and HIV clinical care, and participate in a 10-hour training course with coaching sessions offered over the course of the study to ensure effective and consistent performance. Pharmacists will be guided by a manual designed to provide and walk them through the necessary skills to perform the pilot intervention easily and effectively. The manual will provide background information, study goals, and describe the critical components of the IMB-MI model and the HARP pilot interventions. An easy to follow, step-by-step approach to performing the intervention will be included. The study protocol to be followed by the clinical pharmacists will be included in the manual along with additional motivational and troubleshooting strategies. Systematic feedback regarding intervention fidelity will be provided by the Evaluation Team.",[13],"Behavioral: Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique","Delivered by a clinical pharmacist who will employ IMB-MI in informational, participant-centered discussions in which the clinical pharmacist and the participant collaboratively discuss the harms of alcohol use (with or without concurrent use of cannabis) and polypharmacy (specifically neurocognitively active medications), the relationship of these exposures to fall risk and NCEs, and how to mitigate these harms. Together pharmacist and participant will develop a plan for change in alcohol and polypharmacy use, self-monitoring, medications of concern, symptoms, and any additional resources needed. The goal of the intervention being to help patients stop or decrease alcohol use and stop medications in situations where it is safe to do so and agreed upon by the primary provider (but substitutions will be made if necessary).",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Amy C Justice, MD, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","203-932-5711","3541","amy.justice2@va.gov",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":20},"VA Connecticut Healthcare System","RECRUITING","West Haven","Connecticut","06516","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-72.94705,41.27065,{"lat":44,"lon":43},{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[49],{"name":50,"class":51},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","NIH","100555571","phase-1-hiv-and-alcohol-research-center-focused-on-polypharmacy-harp-pilot-2-2nd-harp-pilot-intervention-100555571",false,"NCT06513819","HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)","HARP","Inclusion Criteria:\n\n* HIV+\n* have visited a local VA site in within the past year\n* had an AUDIT-C indicating current alcohol use\n* taking 5 or more non-ART medications, including an NCAM (i.e., benzodiazepines, opioids, muscle relaxants, sleeping medication, and selective serotonin reuptake inhibitors)\n\nExclusion Criteria:\n\n* Inpatient individuals\n* Patients with an Alcohol Use Disorder (AUD) diagnosis in the past 12 months\n* Patients who test positive on the Alcohol Symptom Checklist for moderate or severe AUD during the screening process","ALL","50 Years",{"count":62,"type":63},100,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","The focus of this pilot will be on falls and neurocognitive symptoms, and the impact of alcohol, cannabis use, and medications on these outcomes. The rationale is that alcohol use at any level may interact with neurocognitively active medications, alcohol, and cannabis use leading to falls and impaired cognition.",[69,70,71,72],"Hiv","Alcohol Drinking","Fall","Cannabis Use","2026-01-13",{"date":75,"type":76},"2026-01-15","ACTUAL",{"date":78,"type":76},"2025-01-15",{"date":80,"type":63},"2026-06",{"name":5,"class":6},1]